GlassScriptPhysician profile
Kimberly Joy Kinnebrew
NPI 1437186889
$3,538.07
in general payments reported to CMS, 2019-2025
21 companies · $968 in 2025
The $968 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $572 · 2022: $129 · 2023: $963 · 2024: $906 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,642 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,642.21 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $897.77 | 2021-2025 | |
| Abbvie INC. | $738.28 | 2021-2025 | |
| Janssen Biotech, INC. | $555.57 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $237.42 | 2021-2025 | Ebglyss, Taltz |
| Ucb, INC. | $184.36 | 2024-2025 | Bimzelx |
| Leo Pharma INC. | $133.38 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $127.42 | 2023-2024 | Sotyktu |
| Genzyme Corporation | $109.04 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $95.47 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $86.36 | 2021 | |
| Amgen INC. | $77.11 | 2023-2025 | Otezla |
| Incyte Corporation | $71.84 | 2021-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $64.63 | 2021-2024 | Dupixent |
| Dermira, INC. | $34.70 | 2021 | |
| Vyne Pharmaceuticals INC. | $23.41 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $21.91 | 2021 | |
| Organon LLC | $21.37 | 2025 | Vtama |
| Sandoz INC. | $19.06 | 2023 | Hyrimoz |
| Organogenesis INC. | $18.74 | 2024 | |
| Pfizer INC. | $13.13 | 2021 | |
| Janssen Scientific Affairs, LLC | $7.10 | 2023 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Kinnebrew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.